Vivesto

Vivesto is a publicly traded Swedish biotech focused on developing novel small molecule drugs for high-need oncology indications in humans and animals. Its strategy centers on advancing a lean pipeline—including the hematological cancer candidate Cantrixil and the veterinary reformulation Paccal Vet—to clinical proof-of-concept before out-licensing. Recent corporate actions, such as a proposed reverse share split, indicate efforts to stabilize its financial structure while progressing key preclinical and clinical studies.

Expertise in reformulating and advancing small molecule chemotherapeutics, utilizing technologies like micellar formulation to improve drug delivery and application for specific oncology indications.

Faces intense competition in human hematological cancers from large pharma and novel modalities like CAR-T and bispecific antibodies. In veterinary oncology, competes against other chemotherapies and emerging targeted therapies, where differentiation will depend on demonstrating improved efficacy, safety, or convenience for Paccal Vet.